A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA)

Conditions: Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Interventions: Drug: Solriamfetol; Drug: Placebo Sponsors: Ignis Therapeutics (Suzhou) Limited Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials